argenx NV ADR (ARGX)vsNektar Therapeutics (NKTR)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
NKTR
Nektar Therapeutics
$72.08
-1.21%
HEALTHCARE · Cap: $2.07B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 7570% more annual revenue ($4.24B vs $55.23M). ARGX leads profitability with a 30.5% profit margin vs -297.1%. NKTR appears more attractively valued with a PEG of 0.31. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
NKTR
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for NKTR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Trading at 16.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -217.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : NKTR
The strongest argument for NKTR centers on PEG Ratio. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : NKTR
The primary concerns for NKTR are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while NKTR is a turnaround play — different risk/reward profiles.
NKTR carries more volatility with a beta of 1.23 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 28/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Nektar Therapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?